How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/low-grade-b-cell-non-hodgkin-lymphoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Low-grade B cell non-Hodgkin lymphoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-grade B cell non-Hodgkin lymphoma (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Low-grade B cell non-Hodgkin lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Fludara	FLUDARABINE PHOSPHATE	Nihon Schering K.K.	Nucleoside Metabolic Inhibitor	Carbonic anhydrase 5A, mitochondrial	1991-01-01
Fludarabin	Fludarabin	Azienda Ospedaliera San Giovanni Battista		Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit
Fludara	Fludara	Celyad Oncology SA		Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Azienda Ospedaliera San Giovanni Battista · 1 drug in Low-grade B cell non-Hodgkin lymphoma
Celyad Oncology SA · 1 drug in Low-grade B cell non-Hodgkin lymphoma
Nihon Schering K.K. · 1 drug in Low-grade B cell non-Hodgkin lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Low-grade B cell non-Hodgkin lymphoma:

Cite this brief

Drug Landscape (2026). Low-grade B cell non-Hodgkin lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/low-grade-b-cell-non-hodgkin-lymphoma. Accessed 2026-06-10.

Low-grade B cell non-Hodgkin lymphoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing